双歧杆菌三联活菌片辅助治疗对肝硬化合并自发性腹膜炎患者肠黏膜屏障功能的影响

Effect of Bifidobacterium Triple Viable Tablets on Intestinal Mucosal Barrier Function in Patients with Liver Cirrhosis Complicated with Spontaneous Bacterial Peritonitis

目的:观察双歧杆菌三联活菌片辅助治疗对肝硬化合并自发性细菌性腹膜炎(SBP)患者肠黏膜屏障功能的影响。方法:选取60例肝硬化合并SBP患者,根据随机数字表法分为对照组和观察组,各30例。对照组采用常规措施治疗,观察组在对照组治疗基础上加用双歧杆菌三联活菌片口服治疗,两组治疗时间均为2周。比较两组治疗总有效率及发热、腹部压痛、反跳痛缓解时间,采用酶联免疫吸附法检测并比较两组患者治疗前后血清二胺氧化酶(diamine oxidase,DAO)和D-乳酸(D-lactic acid,D-Lac)表达水平。结果:观察组治疗总有效率(86.67%)明显高于对照组(66.67%),差异有统计学意义(P<0.05)。观察组患者发热、腹部压痛及反跳痛缓解时间均明显短于对照组,差异均有统计学意义(P<0.05)。治疗前,两组患者血清DAO、D-Lac表达水平比较,差异均无统计学意义(P>0.05);治疗后,两组患者血清DAO、D-Lac表达水平均明显低于治疗前,差异均有统计学意义(P<0.05);且观察组治疗后血清DAO、D-Lac表达水平均明显低于对照组,差异均有统计学意义(P<0.05)。结论:双歧杆菌三联活菌片辅助治疗肝硬化合并SBP患者效果显著,可明显缓解临床症状体征和改善肠黏膜屏障功能。

Objective:To observe the effect of Bifidobacterium Triple Viable Tablets on intestinal mucosal barrier function in patients with liver cirrhosis complicated with SBP.Method:60 patients with liver cirrhosis complicated with SBP were selected and divided into control group and observation group according to the random digital table method,30 cases in each group.The control group was treated with routine treatment measures,while the observation group was treated with Bifidobacterium Triple Viable Tablets on the basis of the control group.The treatment time of both groups were 2 weeks.The total effective rate,fever,abdominal tenderness and rebound tenderness remission time of the two groups were compared.The levels of serum diamine oxidase(DAO)and D-lactic acid(D-Lac)of the two groups before and after treatment were detected by enzymelinked immunosorbent assay.Result:The total effective rate of treatment in the observation group was 86.67%,significantly higher than 66.67% in the control group,the difference was statistically significant(P<0.05).The time of fever,abdominal tenderness and rebound tenderness relief in the observation group were significantly shorter than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the levels of DAO and D-LAC between the two groups before treatment(P>0.05).After treatment,the levels of DAO and D-LAC in the two groups were significantly lower than those before treatment,the differences were statistically significant(P<0.05),and the levels of DAO and D-LAC in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Bifidobacterium Triple Viable Tablets has an effective in adjuvant treatment of liver cirrhosis patients with SBP,it can significantly relieve clinical symptoms and signs,and improve intestinal mucosal barrier function.